He did give some insights, he was also careful.
Roughly he said we are going up...
The how high has too many variables to be precise...
He should play the guessing game with us lol
"Last year's revenues were $34 million. Our goal for the current fiscal year was $40 million. Then I think around November, I modified the number to north of $40 million. And in February, we thought, okay, we're going to hit $50 million, and we ended up with $56 million. Well, that's embarrassing.
But I've learned from my mistakes, Therefore, I am not going to say that this year, our revenues are going to be $60 million. And then in November, I'll tell you we're going to go north of $60 million and February, Ops we're going to hit $70 million. I'm just going to skip all of that right now and go straight for skipping the 60s, I'm predicting that we're going to hit a minimum of $70 million for the fiscal year ending March 2025. You are not sitting in the room, but Carter just hinted, and I think maybe Nasrat hinted too.
However, that is the least I can expect on the current run rate. I have no doubt and no issues we're going to achieve that. What I think will happen is that some of you will start calling Dianne now and saying, well, he said $70 million, does that mean in November, he's going to say we're going to be north of $70 million, and then by February, he's going to say we're going to skip to $80 million? That is not what I'm saying. But if that happened, it would be embarrassing.
Not long ago, our income was in the single digits, $7 million. Then we graduated to the teens, 20s, 30s, we skipped the 40s and now we're in the 50s, and we're going to give skip to 70s and go into 60, that's all because of our sales and distribution and the excellent pipeline we have been working very hard on over the years."
And late rhe said: "Regarding the research and development pipeline, Elite has three ANDAs filed under FDA review. A generic dopamine agonist ANDA for the treatment of Parkinson's disease and ANDA for the treatment of pain management, we have already disclosed its OxyContins, a generic, a central nervous system stimulus ANDA used for attention deficit disorder. Two out of these three are needle movers and approval of one of them would have a huge impact on our revenues for next year. That's when we'll talk about skipping the 70s."
